tbuckley/cabot-search huggingface dataset:
Impact of single and dual neoadjuvant HER2-directed therapy on clinical outcomes among patients with HER2-positive breast cancer (BC).
Authors: Kerry Lynn Reynolds, Ashmeet Bhatia, XingXing Cheng, Barbara Lynn Smith, Michelle Connolly Specht, Beverly Moy, Aditya Bardia
Journal: Journal of Clinical Oncology (2013)

647 Background: While the addition of trastuzumab to neoadjuvant chemotherapy (CTX) is well established for HER2+ BC, the use of dual agent HER2 blockade in the preoperative setting is not considered standard of care. We conducted a comprehensive systematic review and meta-analysis to evaluate the impact of neoadjuvant dual and single agent HER2 blockade on breast conserving surgery (BCS), pathological complete response (pCR) for estrogen receptor (ER)+ and ER- tumors, and impact of pCR on disease-free survival (DFS) and overall survival (OS) for HER2+ BC. Methods: Based on QUORUM guidelines, MEDLINE and Cochrane Controlled Clinical Trials Register databases were queried to identify eligible trials. Inclusion criteria were prospective, neoadjuvant trials that had at least one arm with HER2 directed therapy, and reported pCR. Pooled relative risk ratios (RRs) and 95% confidence intervals (CIs) were estimated for endpoints using the random effects model. Results: We identified 34 trials (N = 4064). High pCR rates (&gt; 40%) were seen with anthracycline-based CTX and trastuzumab, as well as taxane based CTX alone with dual HER2 blockade. The addition of trastuzumab to CTX did not improve BCS rate (RR 1.40, CI: 0.89-2.22, p=.15), but significantly increased rates of pCR (RR 1.91, CI: 1.38-2.64, p=.0001). Similarly, dual HER2 blockade compared to trastuzumab alone did not improve BCS rate (RR 1.03, CI: 0.77-1.38, p=.84), but significantly increased rates of pCR overall (RR 1.38, CI: 1.24-1.53, p&lt;0.00001), in both ER+ (RR 1.72, CI: 1.14-2.61, p=.01) and ER- subsets (RR 1.91, CI: 1.38-2.64, p=.0001). Higher pCR was associated with improved DFS (RR 2.29, CI: 1.27-4.12, p=.006) and OS (RR 4.61, CI: 1.46-14.56, p=.009). Conclusions: Neither the addition of trastuzumab to CTX, nor the dual-HER2 blockade compared to trastuzumab, improves rates of BCS, but both significantly improve rates of pCR, which is associated with improved DFS and OS. A subgroup of HER2+ BC patients can achieve pCR with dual HER2 blockade without dependence on anthracycline-based therapy. Predictive biomarkers are needed to improve patient selection and personalize the optimal regimen for HER2+ BC.
Efficacy and Safety of a Single-Course of Yttrium-90 Ibritumomab Tiuxetan for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma after/not Appropriate for Autologous Stem Cell Transplantation - Final Analysis of a Phase II Trial of the European MCL Network.
Authors: Oliver Weigert, Christoph von Schilling, Mathias J. Rummel, Antonio Pezzutto, Michael Unterhalt, Wolfgang Hiddemann, Martin H. Dreyling
Journal: Blood (2007)
Integrated local binary pattern texture features for classification of breast tissue imaged by optical coherence microscopy
Authors: Sunhua Wan, Hsiang-Chieh Lee, Xiaolei Huang, Ting Xu, Tao Xu, Xianxu Zeng, Zhan Zhang, Yuri Sheikine, James L. Connolly, James G. Fujimoto, Chao Zhou
Journal: Medical Image Analysis (2017)
Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis.
Authors: Evangelos Terpos, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Athanasios Papatheodorou, Evangelos Eleutherakis-Papaiakovou, Efstathios Manios, Efstathios Kastritis, Christos Papadimitriou, Meletios A. Dimopoulos
Journal: Blood (2009)
Abstract P4-07-11: MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer
Authors: G Xiao, J Zhang, X Sun, S Qin, B Zhang, D Liu, J Liu, H Ren
Journal: Cancer Research (2017)

Abstract Increasing studies showed that MicroRNAs (miRNAs)participate in the carcinogenesis and progression of breast cancer, but the specific mechanism of miRNAs in breast cancer needs to be furtherexplored. in this study, wefound that miR-367a was significantly up-regulated in breast cancer tissue samples and cell lines, compared to paired normal tumor-adjacent samples and MCF-10A. meanwhile, Kaplan–Meier analysis demonstrated high miR-367a expression was evidently correlated with poor prognostic features of breast cancer. overexpression of miR-367a remarkably promoted proliferation, cell cycle,inhibited apoptosis ratios and stem-like capacity of breast cancer cells in vitro, whilesilencing the expression of miR-367a dramaticallyreversed these cellular events .in addition,In vivo studies showed that knockdown of miR-367a inhibited tumor growth of breast cancer ,moreover, F-box and WD repeat domain-containing 7 (FBXW7) was identified as a direct target genes of miR-367a, as miR-367a directly bound to the 3'untranslated region of FBXW7 . Notably, alterations of FBXW7 levels abrogated the effects of miR-367a on breast cancer cell proliferation, cell cycle, apoptosis and stemness potential. In conclusion,evidence from this study demonstrated that miR-367amay serve as a novel prognostic indicator for breast cancer patients andexerts tumor promotion,at least in part, by inhibiting FBXW7. Key words: miR-367a, FBXW7, breast cancer, tumor growth, stem-like capacity. Citation Format: Xiao G, Zhang J, Sun X, Qin S, Zhang B, Liu D, Liu J, Ren H. MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-07-11.
Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities
Authors: Fiona M. Menzies, Angeleen Fleming, Andrea Caricasole, Carla F. Bento, Stephen P. Andrews, Avraham Ashkenazi, Jens Füllgrabe, Anne Jackson, Maria Jimenez Sanchez, Cansu Karabiyik, Floriana Licitra, Ana Lopez Ramirez, Mariana Pavel, Claudia Puri, Maurizio Renna, Thomas Ricketts, Lars Schlotawa, Mariella Vicinanza, Hyeran Won, Ye Zhu, John Skidmore, David C. Rubinsztein
Journal: Neuron (2017)
A Novel Role of NF-YA Transcription Factor in in Vitro Adipocyte Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells
Authors: Charalampos Pontikoglou, Anthi Demetriadou, Konstantia I. Pavlaki, Emmanouil Simantirakis, Joseph Papamatheakis, Maria-Christina Kastrinaki, Helen Papadaki
Journal: Blood (2012)
High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.
Authors: Walter B. Walter, Todd A. Alonzo, Robert B. Gerbing, Franklin O. Smith, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Janet L. Franklin, Craig A. Hurwitz, Michael R. Loken, Soheil Meshinchi
Journal: Blood (2009)
Epidemiology of Bacterial Infections during Induction Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the Graall-2005 Study
Authors: Fressia Honeyman, Emmanuelle Tavernier, Valentine Richez, Thibaut Leguay, Fabien Tinquaut, Lenaïg Le Clech, Yosr Hicheri, Stephane Lepretre, Karin Bilger, Gabriela M. Baerlocher, Ana Berceanu, Maria Pilar Gallego Hernanz, Victoria Cacheux, Yves Chalandon, Véronique Lhéritier, Clara Mariette, Faezeh Legrand, Denis Guyotat, Norbert Ifrah, Hervé Dombret, Xavier Thomas
Journal: Blood (2016)
Coming of age and building of bridges … reflections on the past, present, and, hesitatingly, future
Authors: Irwin M. Arias
Journal: Hepatology (2017)

1National Institutes of HealthBethesdaMD *ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:Irwin M. Arias, M.D.National Institutes of HealthBethesda, MD 20814Tel: + 1‐301‐402‐8394E‐mail: [email protected]
Autologous Stem Cell Transplantation (ASCT) in HIV Associated Lymphoma (HIV-Ly) Patients: The EBMT Lymphoma Working Party (EBMT-LWP) Experience.
Authors: Pascual Balsalobre, David Serrano, Alessandro Re, Anne Rosselet, Eulogio Conde, Josep-Maria Ribera, Bernardino Allione, Gaelle Guillerm, Philippe Genet, Ildefonso Espigado, Ann E. Hunter, Marcus Hentrich, Pierre Biron, Augustin Ferrant, Dirk Meyer, Carmen Canals, Goli Taghipour, Jose L. Diez-Martin, Anna Sureda
Journal: Blood (2006)
Guideline: An expert panel found that calcium intake is safe from a cardiovascular perspective
Authors: Bruce E. Johnson, Elvis R. Pagan
Journal: Annals of Internal Medicine (2017)

Source Citation Kopecky SL, Bauer DC, Gulati M, et al. Lack of evidence linking calcium with or without vitamin D supplementation to cardiovascular disease in generally healthy adults: a clinical guideline from the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Ann Intern Med. 2016;165:867-8. 27776362
PP70. WORKING IN PARTNERSHIP: A MODEL FOR A SUCCESSFUL BRAIN TUMOUR SUPPORT GROUP
Authors: Ms Audrey Hopwood, Mr Ian Edwards
Journal: Neuro-Oncology (2017)

The Clinical Nurse Specialists in Neuro-oncology at University Hospitals Coventry and Warwickshire have 23 years experience of skills and knowledge which enables them to effectively support patients; their families and carers. Within this time the way in which patients and their families look for and receive information and support has changed. Patients now have access to individual care planning; tailored holistic needs assessments and information accessible at the point of need. During assessments patients; their families and carers often ask to meet other people in similar circumstances, to discuss their experiences and share ideas. In order to facilitate this process the Clinical Nurse Specialists in collaboration with the Brainwaves charity set up the Coventry Brain Tumour Support Group in 2012. Further partnership with Brain Tumour Support commenced in 2014. The support group aims are to: • Talk and share experiences • Provide a relaxing environment • Provide coping and self-help strategies • Provide appropriate information in the form of invited speakers • Discuss brain tumour issues • Have a supported social friendship group The poster will present the successes and challenges of developing an appropriate and sustainable support network for brain tumour patients and their families/carers., highlighting the increasing number since its launch. It will also show how patients have taken advantage of the many social events organised such as pamper sessions, garden centre visits, barbeques and skittles nights. The poster will also demonstrate how working in collaboration with both local and national charities has benefited patients; and how partnership working has contributed considerably to the success of the Coventry Brain Tumour Support Group.
Abstract 57: Therapeutic Effects of Small Molecule Gβγ Inhibition in Pressure Overload Heart Failure
Authors: Fadia A Kamal, Alan V Smrcka, Burns C Blaxall
Journal: Circulation Research (2012)

Heart failure (HF) is a progressive disease with rapidly increasing rates of morbidity and mortality; it is the leading cause of death worldwide. Elevated sympathetic nervous system activity, a salient feature of HF progression, leads to pathologic attenuation and desensitization of β-adrenergic receptors (β-ARs) due in part to Gβγ-mediated signaling. We recently reported that novel small molecule Gβγ inhibitors selectively block specific Gβγ signals and halt HF progression in pharmacologic and transgenic mouse models of HF. We assessed the hypothesis that the Gβγ inhibitor Gallein could be salutary in treating pre-existing HF in a clinically relevant model. We utilized the pressure-overload HF model of mouse transverse aortic constriction (TAC). Four weeks post-TAC, mice received daily IP injections of vehicle (PBS; group V) or Gallein (10mg/Kg/day; group G) for eight weeks. Gallein treatment improved survival (7 of 9 mice survived vs. 5 of 9 mice in group V) and cardiac function (%EF 75.2 ± 7.5 vs 35.6 ± 17.2 in group V, +dP/dt (mmHg/sec) 7022 ± 485.3 vs. 3584 ± 598.6 in group V), -dP/dt (mmHg/sec) -5826 ± 910.7 vs. -3260 ± 62.3 in group V, LVEDP (mmHg) 11.5 ± 3.7 vs. 29.45 ± 3.6 in group V). In addition, gallein reduced cardiac hypertrophy (HW/BW (mg/g) 5.8 ± 0.3 vs. 8.8 ± 1.1 in group V) and plasma catecholamine concentrations (adrenaline (ng/ml) 1.3 ± 0.3 vs. 6.6 ± 2.8 in group V, noradrenaline (ng/ml) 3.6 ± 0.6 vs. 15.1 ± 3.6 in group V). Reduction of interstitial fibrosis as well as mRNA levels of α-SMA, TNF-α, and IL-6 was observed in the hearts of Gallein treated animals (59.7 ± 14.1%, 43.8 ± 9.3% and 28.5 ± 3.5% relative to group V, respectively). On the molecular level, Gallein treated mice showed less GRK2 and PI3Kγ membrane recruitment, and less Akt activation (42.9 ± 7.1%, 66.7 ± 13.3% and 46.2 ± 7.7% relative to group V, respectively) in myocardial lysates. In conclusion , these data suggest a possible therapeutic role for small molecule Gβγ inhibition in halting the progression of HF, potentially via inhibition of the Gβγ-GRK2-PI3Kγ-Akt pathway. The combined effect of halting HF progression and reducing plasma catecholamines suggests a possible systemic role for small molecule Gβγ inhibition in both the heart and the adrenal gland.
Patterns of Hospitalization in Elderly Patients with Asthma and Chronic Obstructive Pulmonary Disease
Authors: RITA K. CYDULKA, E. R. McFADDEN, CHARLES L. EMERMAN, LYNN D. SIVINSKI, WENDY PISANELLI, ALFRED A. RIMM
Journal: American Journal of Respiratory and Critical Care Medicine (1997)

The purpose of this study was to describe the impact of asthma and chronic obstructive pulmonary disease (COPD) in the elderly on health care utilization. The Health Care Financing Administration (HCFA) file for the year 1984 through 1991 involving beneficiaries ⩾ 65 yr were searched for the diagnoses of asthma and COPD by ICD-9 codes. The study groups were created by determining the first admission for an exacerbation of either disease during each year from 1984 through 1991. Patients were identified by their social security number. The 1984 cohort consisted of 56,692 patients with asthma exacerbation and 162,899 with COPD exacerbation. The 1991 cohort consisted of 67,758 patients with asthma exacerbation and 131,974 patients with COPD exacerbation. In addition, the 1984 cohort was tracked by social security number for evidence of rehospitalization for either asthma or COPD through 1991. Length of hospitalization increased as patients grew older. The discharge rate to an independent living facility diminished as age increased. The use of convalescent and nursing homes or home health care after discharge more than doubled from 1984 through 1991. The utilization of health care resources by elderly patients with asthma and COPD is immense, both during hospitalization and after discharge.
An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy
Authors: Giacomo Frati, Leonardo Schirone, Isotta Chimenti, Derek Yee, Giuseppe Biondi-Zoccai, Massimo Volpe, Sebastiano Sciarretta
Journal: Cardiovascular Research (2017)

Heart failure is a highly morbid and mortal clinical condition that represents the last stage of most cardiovascular disorders. Diabetes is strongly associated with an increased incidence of heart failure and directly promotes cardiac hypertrophy, fibrosis, and apoptosis. These changes, in turn, contribute to the development of ventricular dysfunction. The clinical condition associated with the spectrum of cardiac abnormalities induced by diabetes is termed diabetic cardiomyopathy. Myocardial inflammation has recently emerged as a pathophysiological process contributing to cardiac hypertrophy, fibrosis, and dysfunction in cardiac diseases. Myocardial inflammation is also implicated in the development of diabetic cardiomyopathy. Several molecular mechanisms link diabetes to myocardial inflammation. The NF-κB signalling pathway and the renin-angiotensin-aldosterone system are strongly activated in the diabetic heart, thereby promoting myocardial inflammation. Advanced glycation end-products and damage-associated molecular pattern molecules also represent strong triggers for inflammation. The mediators resulting from this inflammatory process modulate specific intracellular signalling mechanisms in cardiac cells that promote the development of diabetic cardiomyopathy. This review article will provide an overview of the signalling molecular mechanisms linking diabetic cardiomyopathy to myocardial inflammation.
Exploration of the metal coordination region of concanavalin A for its interaction with human norovirus
Authors: Duwoon Kim, Hee-Min Lee, Kyung-Seo Oh, Ah Young Ki, Rachael A. Protzman, Dongkyun Kim, Jong-Soon Choi, Min Ji Kim, Sung Hyun Kim, Bipin Vaidya, Seung Jae Lee, Joseph Kwon
Journal: Biomaterials (2017)
Myeloid neoplasms with concurrent <i>BCR‐ABL1</i> and <i>CBFB</i> rearrangements: A series of 10 cases of a clinically aggressive neoplasm
Authors: Alireza Salem, Sanam Loghavi, Guilin Tang, Yang O. Huh, Elias J. Jabbour, Hagop Kantarjian, Wei Wang, Shimin Hu, Rajyalakshmi Luthra, L. Jeffrey Medeiros, Joseph D. Khoury
Journal: American Journal of Hematology (2017)

Chronic myeloid leukemia (CML) is defined by the presence of t(9;22)(q34;q11.2)/BCR-ABL1. Additional chromosomal abnormalities confer an adverse prognosis and are particularly common in the blast phase of CML (CML-BP). CBFB rearrangement, particularly CBFB-MYH11 fusion resulting from inv(16)(p13.1q22) or t(16;16)(p13.1;q22), is an acute myeloid leukemia (AML)-defining alteration that is associated with a favorable outcome. The co-occurrence of BCR-ABL1 and CBFB rearrangement is extremely rare, and the significance of this finding remains unclear. We identified 10 patients with myeloid neoplasms harboring BCR-ABL1 and CBFB rearrangement. The study group included six men and four women with a median age of 51 years (range, 20-71 years). The sequence of molecular alterations could be determined in nine cases: BCR-ABL1 preceded CBFB rearrangement in seven, CBFB rearrangement preceded BCR-ABL1 in one, and both alterations were discovered simultaneously in one patient. BCR-ABL1 encoded for p210 kD in all cases in which BCR-ABL1 preceded CBFB rearrangement; a p190 kD was identified in the other three cases. Two patients were treated with the FLAG-IDA regimen (fludarabine, cytarabine, idarubicin, and G-CSF) and tyrosine kinase inhibitors (TKI); seven with other cytarabine-based regimens and TKIs, and one with ponatinib alone. At last follow up (median, 16 months; range 2-85), 7 of 10 patients had died. The co-existence of BCR-ABL1 and CBFB rearrangement is associated with poor outcome and a clinical course similar to that of CML-BP, and unlike de novo AML with CBFB rearrangement, suggesting that high-intensity chemotherapy with TKI should be considered in these patients.
Human Placenta-Derived Adherent Cells Delivered Intralesionally Inhibit Myeloma Bone Disease and Tumor Growth, While Intravenously Are Capable of Trafficking to Myelomatous Bone.
Authors: Xin Li, Wen Ling, Angela Pennisi, Yuping Wang, Sharmin Khan, Mohammad Heidaran, Ajai Pal, Xiaokui Zhang, Shuyang He, Andy Zeitlin, Stewart Abbot, Herbert Faleck, Robert Hariri, John Shaughnessy, Frits van Rhee, Bijay Nair, Bart Barlogie, Joshua Epstein, Shmuel Yaccoby
Journal: Blood (2010)
Abstract 15930: Efficacy and Safety of Apixaban in Patients With Atrial Fibrillation According to Sex: Results From the ARISTOTLE Trial
Authors: Dragos Vinereanu, Susanna R Stevens, John H Alexander, Sana M Al-Khatib, Alvaro Avezum, M. Cecilia Bahit, Christopher B Granger, Renato D Lopes, Sigrun Halvorsen, Michael Hanna, Steen Husted, Elaine M Hylek, Andrei D Margulescu, Lars Wallentin, Dan Atar
Journal: Circulation (2013)

Background: Prior studies have shown that in patients with AF there may be important differences in clinical outcomes between men and women. We assessed clinical events as well as the efficacy and safety of apixaban compared with warfarin according to sex in patients enrolled in the ARISTOTLE trial.

Methods: Patients enrolled in the ARISTOTLE trial (6416 women, 11785 men) were analyzed. The primary efficacy outcome was stroke or systemic embolism. Secondary efficacy endpoints were death of any cause and CV death. The primary safety outcome was major bleeding. Cox proportional hazards regression models were used to assess associations between clinical outcomes and sex as well as sex-by-treatment interactions.

Results: Women were older than men (72 vs. 69 yrs; p<0.001). The prevalence of prior stroke/ embolic events (20.6% vs. 18.8%), hypertension (89.7% vs. 86.2%), and renal failure (69.6% vs. 52.5%) was higher in women than in men, while men had a higher prevalence of heart failure (36.1% vs. 34.3%), ischemic heart disease (38.5% vs. 29.8%), and bleeding history (17.4% vs. 15.4%). Compared with men, women had a higher baseline stroke risk according to CHADS2 (score ≥3: 34.1% vs. 28.1%; p<0.001), but similar bleeding risk according to the HAS-BLED score. However, the rates of observed stroke and systemic embolic events (HR 1.16, 95% CI 0.97-1.40; p=0.11) and major bleeding (HR 0.98, 95% CI 0.85-1.14; p=0.84) were similar in women versus men. Overall, women had lower risk of death (HR 0.82, 95% CI 0.73-0.92; p=0.001) and CV related death (HR 0.75, 95% CI 0.64-0.89; p=0.001) compared with men. The efficacy and safety of apixaban compared with warfarin were consistent, regardless of sex (Figure).

Conclusions: In ARISTOTLE, the risks of stroke and of major bleeding were similar in women and men despite the lower mortality (both of any cause and CV) in women compared with men. The efficacy and safety benefits of apixaban compared with warfarin were consistent in men and women.

![Graphic][1]  [1]: /embed/inline-graphic-1.gif